Business
PharmaDrug Advances Programs in Oncology with Filing of PCT Application Detailing the Use of PD-001 for Treatment of Prostate Cancer
Toronto, Ontario--(Newsfile Corp. - January 31, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF...
About this update from Pharmadrug, Inc.
[{"type":"text","content":"PharmaDrug Advances Programs in Oncology with Filing of PCT Application Detailing the Use of PD-001 for Treatment of Prostate CancerToronto, Ontario--(Newsfile Corp. - January 31, 2023) - PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (\"PharmaDrug\" or the \"Company\"), a specialty pharmaceutical company focused on the research, development and commercialization of psychedelics and other naturally-derived approved drugs, is pleased to announce that the Company has completed filing a PCT (Patent Cooperation Treaty) application for its lead drug, cepharanthine-2HCL (PD-001) for the treatment of prostate cancer, alone or in combination with standard of care chemotherapeutics, as well as for other indications where the drug has shown efficacy in preclinical studies. This move is expected to build significant value for the Company's investors. Filing of the PCT provides the Company with 18 months to formally elect and pursue patent protection in any of 153 member countries, including countries of strategic interest such as the United States, Canada, Japan and China.\"We are excited to take this important step in the development of PD-001 as a treatment for prostate cancer and other indications. This PCT patent filing is a significant milestone that will solidify our intellectual property portfolio and provide a clear path for commercialization,\" said Daniel Cohen, CEO of PharmaDrug. \"This move is expected to create significant value for our investors as we bring this potentially life-saving treatment to patients around the globe suffering from these diseases.\"PD-001 is a novel compound with a unique mechanism of action that has shown promising results in preclinical studies for the treatment of a wide range of diseases. These include but are not limited to prostate cancer, colorectal cancer, breast cancer and infectious disease as well as several others. The PCT patent filing will enable PharmaDrug to simultaneously seek protection for its intellectual property in multiple countries worldwide and will support claims related to the use of PD-001 alone or in combination with already approved chemotherapeutic agents. This is expected to provide a strong competitive advantage and a solid foundation for the commercialization of the drug.Claims Set Forth in PCT Filing Centered Around Demonstrated Benefit of PD-001 in Pre-Clinical Prostate ...